Table 3.
Univariate and multivariate analysis of risk factors associated with DMFS and OS in ESCC patients treated with dCRT.
| DMFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Predictive Variables | Univariate Analysis | Multivariate Analysis a | Univariate Analysis | Multivariate Analysis a | ||||
| HR (95% CI) | P-Value | HR (95% CI) | P-Value | HR (95% CI) | P-Value | HR (95% CI) | P-Value | |
| Age, years | 0.97 (0.94–1.01) | 0.092 | 0.96 (0.92–0.99) | 0.020 | 1.01 (0.98–1.03) | 0.589 | ||
| ECOG | ||||||||
| 0 vs. 1/2 (ref) | 1.02 (0.52–2.00) | 0.948 | 0.83 (0.49–1.42) | 0.499 | ||||
| Tumor location | ||||||||
| Upper vs. | 0.93 (0.53–1.63) | 0.806 | 0.83 (0.54–1.27) | 0.393 | ||||
| Middle/Lower (ref) | ||||||||
| Initial T-Stage b | ||||||||
| cT4 vs. cT1–3 (ref) | 1.11 (0.63–1.94) | 0.720 | 1.45 (0.94–2.22) | 0.094 | 1.66 (1.06–2.60) | 0.028 | ||
| Initial N-Stage b | ||||||||
| cN3 vs. cN1–2 (ref) | 2.60 (1.48–4.56) | 0.001 | 2.21 (1.18–4.14) | 0.013 | 1.51 (0.97–2.36) | 0.067 | 1.32 (0.82–2.14) | 0.252 |
| Tumor length, cm | 1.04 (0.94–1.16) | 0.450 | 1.04 (0.95–1.13) | 0.424 | ||||
| SUVTumor | 1.06 (1.02–1.09) | 0.001 | 1.08 (1.04–1.12) | < 0.001 | 1.01 (0.98–1.04) | 0.488 | ||
| SUVLN | 1.10 (1.06–1.14) | < 0.001 | 1.04 (1.02–1.07) | 0.003 | ||||
| SUVLN/SUVTumor | 1.99 (1.29–3.05) | 0.002 | 2.24 (1.34–3.75) | 0.002 | 1.57 (1.06–2.35) | 0.026 | 1.61 (1.03–2.53) | 0.037 |
| Chemotherapy | ||||||||
| Paclitaxel/Cisplatin or Carboplatin | 1.22 (0.69–2.15) | 0.495 | 0.96 (0.62–1.49) | 0.848 | ||||
| Cisplatin/5-FU (ref) | ||||||||
| Radiotherapy | 0.533 | 0.321 | ||||||
| Initial dose < 5000 cGy without consolidative boost |
1.47 (0.70–3.09) | 0.315 | 1.54 (0.86–2.76) | 0.145 | ||||
| Initial dose < 5000 cGy with consolidative boost |
1.04 (0.54–2.00) | 0.918 | 1.13 (0.67–1.91) | 0.640 | ||||
| Initial dose ≥ 5000 cGy (ref) | ||||||||
CI: Confidence interval; dCRT: Definitive chemoradiotherapy; DMFS: Distant metastasis-free survival; ECOG: Eastern Cooperative Oncology Group performance score; 5-FU: 5-Fluorouracil; HR: Hazard ratio; LN: Lymph node; OS: Overall survival; SUV: Standardized uptake value. a Due to multicollinearity (r > 0.70) between SUVLN/SUVTumor and SUVLN, SUVLN was not included in the multivariate Cox model. All other factors with p < 0.1 in the univariate analysis were included in the Cox multivariate analysis. b Clinical staging according to TNM classification, 7th edition.